Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose-Escalation, Single Arm, Combination Study of Cabazitaxel with Gemcitabine to Determine the Safety and Pharmacokinetics in Subjects with Advanced Solid Malignancies (Sanofi-Aventis TCD11068).

Trial Profile

A Dose-Escalation, Single Arm, Combination Study of Cabazitaxel with Gemcitabine to Determine the Safety and Pharmacokinetics in Subjects with Advanced Solid Malignancies (Sanofi-Aventis TCD11068).

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 14 Sep 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabazitaxel (Primary) ; Gemcitabine (Primary) ; Midazolam
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 20 Jan 2012 Actual patients number is 22 as reported by ClinicalTrials.gov.
  • 20 Jan 2012 Planned end date changed from 1 Jun 2013 to 1 Oct 2011 as reported by ClinicalTrials.gov.
  • 20 Jan 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top